Molecular Partners AG - ADR
MOLN
Get informed when a big investor buys or sells
+ FollowMarket Cap$150.42M
Close$
$2.55
31.8% downside
Current Fair Value
31.8% downsideOvervalued by 31.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $150.42 Million |
|---|---|
| Enterprise Value | $85.76 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.65 |
| Beta | 0.69 |
| Outstanding Shares | 38,786,000 |
Return
| Return on Equity | -94.35% |
|---|---|
| Return on Assets | -72.97% |
| Return on Invested Capital | -85.16% |
Valuation & Multiples
| P/E Ratio | -2.36 |
|---|---|
| PEG | 7.28 |
| Price to Sales | - |
| Price to Book Ratio | 3.75 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -1.53 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.04 |
| Debt to Equity | 0.05 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 25, 2026
EPS Estimate
$-0.45
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
October 29, 2026
EPS Estimate
$-0.46
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 9.26%▼ 0.31% |
|---|---|
| Total Invested | $13.81M▼ 3.03% |
| Investors Holding | 5▲ 1.00% |
ESG Score
No data
About Molecular Partners AG
149 employees
CEO: Patrick Amstutz Molecular Partners AG is a clinical-stage biopharmaceutical company that specializes in the discovery, development, and commercialization of novel therapeutic proteins, leveraging its proprietary DARPin® technology. Its pipeline features...